- Home
- INVE vs ASRT Comparison
INVE vs ASRT Comparison
Compare INVE & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVE | ASRT |
|---|---|---|
| Founded | 1990 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.8M | 76.0M |
| IPO Year | 1997 | 2004 |
Fundamental Metrics
Financial Performance| Metric | INVE | ASRT |
|---|---|---|
| Price | $3.70 | $11.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $5.50 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 37.7K | 24.1K |
| Earning Date | 06-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1182.76 | 95.07 |
| EPS | N/A | ★ N/A |
| Revenue | $60,219,000.00 | ★ $124,961,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.82 | $1.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 7.21 | N/A |
| 52 Week Low | $2.86 | $0.51 |
| 52 Week High | $4.07 | $12.95 |
Technical Indicators
Market Signals| Indicator | INVE | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 65.95 | 48.76 |
| Support Level | $3.25 | $11.05 |
| Resistance Level | $3.84 | $12.45 |
| Average True Range (ATR) | 0.19 | 0.46 |
| MACD | 0.04 | -0.16 |
| Stochastic Oscillator | 65.48 | 30.00 |
Price Performance
Historical ComparisonAbout INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.